More general incorporation of hemoglobin level into response criteria for myelodysplastic syndrome and acute myeloid leukemia with increase in minimum red cell transfusion levels

References

• McQuilten ZK, Busija L, Seymour J, et al. Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia. Leukemia and Lymphoma.
   Web of Science ®Google Scholar
• Platzbecker U, Fenaux P, Adès L, et al. Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials. Blood. 2019;133(10):1020–1030.
   PubMed Web of Science ®Google Scholar
• Jairath V, Kahan BC, Gray A, et al. Restrictive versus liberal blood transfusion for acute upper gastrointestinal bleeding (TRIGGER): a pragmatic, open-label, cluster randomised feasibility trial. Lancet. 2015;386(9989):137–144.
   PubMed Web of Science ®Google Scholar
• Hajjar LA, Vincent JL, Galas FR, et al. Transfusion requirements after cardiac surgery: the TRACS randomized controlled trial. Jama. 2010;304(14):1559–1567.
   PubMed Web of Science ®Google Scholar
• Carson JL, Carless PA, Hebert PC. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev. 2012;4(4):Cd002042.
   PubMedGoogle Scholar
• Malcovati L. Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. Leuk Res. 2007;31 Suppl (3):S2–S6.
   Google Scholar
• Greenberg PL. Myelodysplastic syndromes: iron overload consequences and current chelating therapies. J Natl Compr Canc Netw. 2006;4(1):91–96.
   PubMedGoogle Scholar
• Sanz C, Nomdedeu M, Belkaid M, et al. Red blood cell alloimmunization in transfused patients with myelodysplastic syndrome or chronic myelomonocytic leukemia. Transfusion. 2013;53(4):710–715.
   PubMed Web of Science ®Google Scholar
• Network NCC. NCCN Clinical Practice Guidlines in Oncology Myelodysplastic Syndromes (Version 3.2021); 2021.
   Google Scholar
• Malcovati L, Hellström-Lindberg E, Bowen D, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the european LeukemiaNet. Blood. 2013;122(17):2943–2964.
   PubMed Web of Science ®Google Scholar
• Efficace F, Kemmler G, Vignetti M, et al. Health-related quality of life assessment and reported outcomes in leukaemia randomised controlled trials – a systematic review to evaluate the added value in supporting clinical decision making. Eur J Cancer. 2008;44(11):1497–1506.
   PubMed Web of Science ®Google Scholar
• Stanworth SJ, Killick S, McQuilten ZK, et al. Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial. Br J Haematol. 2020;189(2):279–290.
   PubMed Web of Science ®Google Scholar
• University LC. Impact of 2 transfusion strategies on quality of life of multitransfused patients with low-risk myelodysplastic syndrome (SMD-transfu). ClinicalTrials.gov. Identifier: NCT03643042.
   Google Scholar
• Angelucci E, Li J, Greenberg P, et al. Iron chelation in transfusion-dependent patients with low- to intermediate-1-risk myelodysplastic syndromes: a randomized trial. Ann Intern Med. 2020;172(8):513–522.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Platzbecker U, Mufti GJ, et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med. 2020;382(2):140–151.
   PubMed Web of Science ®Google Scholar
• Hellström-Lindberg E, Negrin R, Stein R, et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol. 1997;99(2):344–351.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Santini V, Almeida A, et al. Phase III, randomized, placebo-controlled trial of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2021;39(13):1426–1436.
   PubMed Web of Science ®Google Scholar
• Freireich EJ, Gehan EA, Sulman D, et al. The effect of chemotherapy on acute leukemia in the human. J Chronic Dis. 1961;14:593–608.
   PubMedGoogle Scholar
• Øvlisen AK, Oest A, Bendtsen MD, et al. Stringent or nonstringent complete remission and prognosis in acute myeloid leukemia: a Danish population-based study. Blood Adv. 2018;2(5):559–564.
   PubMed Web of Science ®Google Scholar
• Kornblith AB, Herndon JE, 2nd, Silverman LR, et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a cancer and leukemia group B study. J Clin Oncol. 2002;20(10):2441–2452.
   PubMed Web of Science ®Google Scholar
• Appelbaum FR, Rosenblum D, Arceci RJ, et al. End points to establish the efficacy of new agents in the treatment of acute leukemia. Blood. 2007;109(5):1810–1816.
   PubMed Web of Science ®Google Scholar
• Pinchon DJ, Stanworth SJ, Dorée C, et al. Quality of life and use of red cell transfusion in patients with myelodysplastic syndromes. A systematic review. Am J Hematol. 2009;84(10):671–677.
   PubMed Web of Science ®Google Scholar
• Caocci G, La Nasa G, Efficace F. Health-related quality of life and symptom assessment in patients with myelodysplastic syndromes. Expert Rev Hematol. 2009;2(1):69–80.
   PubMed Web of Science ®Google Scholar
• Cannella L, Caocci G, Jacobs M, et al. Health-related quality of life and symptom assessment in randomized controlled trials of patients with leukemia and myelodysplastic syndromes: what have we learned? Crit Rev Oncol Hematol. 2015;96(3):542–554.
   PubMed Web of Science ®Google Scholar
• Abel GA, Klaassen R, Lee SJ, et al. Patient-reported outcomes for the myelodysplastic syndromes: a new MDS-specific measure of quality of life. Blood. 2014;123(3):451–452.
   PubMed Web of Science ®Google Scholar
• Buckley SA, Halpern AB, Othus M, et al. Development and validation of the AML-QOL: a quality of life instrument for patients with acute myeloid leukemia. Leuk Lymphoma. 2020;61(5):1158–1167.
   PubMed Web of Science ®Google Scholar
• Estey EH, Hasserjian RP, Döhner H. Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal. Blood. 2021.
   Web of Science ®Google Scholar